Graded Expression of Snail as Marker of Cancer Development and DNA Damage-Based Diseases
OwnerIsidro Sanchez-Garcia, Felipe Voces-Sanchez +1inventors
InventorsIsidro Sanchez-Garcia, Felipe Voces-Sanchez, Pedro Antonio Perez-Mancera
Life of this patent
Estimating the term…
Abstract
The invention relates to the graded expression level of SNAIL gene or its expression products, as a marker of the capacity of epithelial and mesenchymal tumours and/or cancers for disseminating to other tissues or organs. The invention further relates to a transgenic non-human mammal comprising in its genome a transgene that comprises a nucleic acid sequence encoding the SNAIL protein, and the use of SNAIL as a marker of epithelial and mesenchymal tumours and/or cancers as well as in DNA damage-based diseases In addition, the invention relates to the use of SNAIL as a therapeutic and diagnostic target for said pathologies.
Claims23
A transgenic non-human mammal comprising in its genome a transgene that comprises a nucleic acid sequence encoding the SNAIL protein
(canceled)
Use of a compound which inhibits or decreases the levels of the SNAIL expression products or reverts the effects of an increased level of SNAIL expression products in the manufacture of a pharmaceutical composition for prevention and/or treatment of a tumour selected from an epithelial tumour or a mesenchymal tumour, or of a DNA damage-based disease.
A pharmaceutical composition comprising a therapeutically effective amount of a compound which inhibits or decreases the levels of the SNAIL expression products or reverts the effects of an increased level of SNAIL expression products together with one or more pharmaceutically acceptable excipients and/or carriers.
A kit for determining the invasive and/or metastatic capacity of an epithelial or mesenchymal tumour, or the local growth capacity of an epithelial or mesenchymal tumour, or for in vitro diagnosing a condition in a subject, said condition being selected from an epithelial tumour, a mesenchymal tumour and a DNA damage-based disease, or for determining the stage or severity of said condition in a subject, or for determining the predisposition of a subject to develop said condition, or for monitoring the effect of the therapy administered to a subject with said condition, or for screening, searching, identifying, discovering, developing and/or evaluating compounds for the prevention and/or treatment of a mesenchymal or epithelial tumour or DNA damage-based disease which comprises an antibody that specifically recognizes SNAIL protein in a suitable packing, or primer pair designed to specifically amplify a nucleic acid having a sequence that is specific to SNAIL.
Dependencies are inferred from the claim text.